Status:
NOT_YET_RECRUITING
Effect of Long-Term Use of Tenofovir (TDF) on Bone Density in Patients With Chronic Hepatitis B
Lead Sponsor:
Assiut University
Conditions:
Tenofovir Disoproxil Fumarate
Bone Density
Eligibility:
All Genders
18-60 years
Brief Summary
This study aims to evaluate the effect of long-term use of Tenofovir Disoproxil Fumarate (TDF) on bone density in patients with chronic hepatitis B virus (HBV) infection. Tenofovir is a widely used an...
Detailed Description
Hepatitis B is a viral infection that affects approximately 257 million people worldwide, with an estimated 820,000 deaths annually due to HBV-related complications. It is a leading cause of liver cir...
Eligibility Criteria
Inclusion
- \-
- Adult male or female patients aged 18 to 60 years.
- Diagnosed as HBV-positive.
- Long-term use of Tenofovir Disoproxil Fumarate (TDF) for more than five years.
Exclusion
- Presence of other chronic liver diseases.
- Diagnosed with Chronic Kidney Disease (CKD), regardless of etiology.
- Patients who refuse to participate in the study.
- Patients on combination therapy, including:
- Interferon and Nucleoside analogue combination therapy.
- Multiple nucleoside analogue combination therapy.
- \-
Key Trial Info
Start Date :
May 22 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT06990438
Start Date
May 22 2025
End Date
June 1 2026
Last Update
May 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Assuit
Asyut, Egypt